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Bacteriophage 434 repressor ecognizes the operator sequences ACAAG and ACAAT. As the same or similar sequences occur in the enhancer 
region of HIV-l, 434 repressor was a potential HIV enhancer-binding protein. We found that the interaction of the DNA-binding domain of 434 
repressor with a 57-bp HIV enhancer DNA was very weak whereas a 42-residue construct, comprising the recognition helix and four copies of 
a positively charged segment of the repressor, bound strongly. The results of footprint and cell-free in vitro transcription studies showed that the 
42-residue peptide bound preferably to the enhancer egion of HIV-l and acted as an artificial repressor. Replacement of an essential glutamine 
of the recognition helix by glutamic acid resulted in a partial shift of the sequence specificity of the 42-residue peptide. 
Bacteriophage 434 operator; HIV-l core enhancer; Recognition helix of 434 repressor; 434 repressor-derived HIV enhancer-binding polypeptide; 
DNase I footprint; Inhibition of HIV LTR-controlled in vitro transcription 
1. INTRODUCTION 
Designed sequence-specific DNA-binding polypep- 
tides could be useful tools to study protein-DNA inter- 
actions at the molecular level and may even find practi- 
cal application as repressors of the transcription of cel- 
lular genes or viral genomes including HIV-l. Embark- 
ing on the de novo design of an enhancer-specific HIV- 
inhibitory peptide would therefore be challenging but 
also very time-consuming [ 11. The latter prompted us to 
base this work on a natural model. 
In the operator region of bacteriophage 434 [2], the 
sequences ACAAG and ACAAT occur as nearly sym- 
metric dimers on opposite strands and are recognized 
by the dimeric 434 repressor [2,3]. As the same or simi- 
lar sequences, although monomeric, occur in the en- 
hancer region of HIV-l [4-71 (Fig. la, underlined se- 
quences), we tried to prepare HIV enhancer-binding 
polypeptides based on the structure of the DNA-bind- 
ing domain (residues l-69, Fig. lb) of 434 repressor 
[WI. 
Synthetic 434 repressor l-69 (Fig. lb) did not bind 
to HIV enhancer DNA (Fig. le) at salt concentrations 
>20 mM (Fig. 2, lane 2); probably, the interaction with 
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a single ACAAG or ACTTT site was too weak. Like- 
wise, a 26-residue repressor analogue (Fig. lc, net 
charge +6) containing the recognition helix [3,8] in the 
center and the positively charged sequence 374 at 
each end showed no binding. Duplication of the re- 
pressor sequence 3744 at both ends of the recognition 
helix, however, resulted in a 42-residue polypeptide 
(Fig. Id, net charge +14, henceforth called R42) that 
bound strongly to the HIV enhancer DNA even at a 
cation concentration of -250 mM at pH 7.4 (Fig. 2). 
In the present work, the sequence specificity and in 
vitro activity of the artificial, 434 repressor-derived pol- 
ypeptide and a mutant of its recognition helix were 
studied using band shift electrophoresis, DNase I foot- 
printing, and cell-free in vitro transcription. 
2. EXPERIMENTAL 
2.1. Synthetic peptides and oligodeoxyribonucleotides 
Peptides were synthesized by the automated Merrifield procedure 
[9] and purified by gel filtration, ion exchange chromatography, and 
HPLC. Oligodeoxyribonucleotides were purchased and purified by 
HPLC or on denaturing 20% polyacrylamide gels. 
2.2. Band shifr assay [lO,ll/ of the R42-HIV enhancer DNA interac- 
tion (Figs. 2 and 5) 
Synthetic HIV enhancer DNA (Fig. le and analogues lacking either 
ACAAG or ACTIT) was labelled at the 5’-end by [y-“P]ATP and 
annealed with the unlabelled complementary strand following stand- 
ard procedures [12]. R42 (Fig. Id), R42 Arg”, Glt~~~, R42 A$‘, and 
434 repressor 169 (Fig. lb) were incubated with 200 fmol each of 
labelled enhancer DNA in 20~1 buffer (100 mM potassium phosphate, 
pH 7.4, 60 mM NaCl, 15 mM KCl, 5 mM MgCl,, 0.2 mM EDTA, 
0.1% Nonidet P-40) for 15 min at 37°C and the mixtures applied to 
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37-44 37-43 'ycon 37-44 37-44 
-108 -91 
e 5'-AAGAACTGCTGACATCGAGCTTGCTACAAGGGGAC~TCCGCTGGGCCAGGGAGGCGT-3' -- 
I I 
f 5'-AAGAACTGCTGACATCGAGCTTGCTGTGCAGGF GCTGGGCCAGGGAGGCGT-3' 
Fig. 1. Polypeptide and DNA sequences relevant o the present study. a, enhancer egion of HIV-l, segments identical or similar to 434 operator 
sequences are underlined; b, DNA-binding domain of 434 repressor (recognition helix underlined); c, synthetic 26residue analogue of 434 repressor 
composed of residues 3743, valine, glycine, the recognition helix and residues 3744; d, synthetic 42-residue analogue of 434 repressor (R42, 
composition as indicated); e, synthetic HIV enhancer DNA (57 bp); to avoid clustering of potential binding sites, one of the two ACTTT sequences 
(-88 to -83) was omitted; the heavy bar marks the region protected from DNase I digestion by R42; f, synthetic 51-bp analogue of the enhancer 
DNA shown in e lacking the ACAAG and ACTTT sequences. 
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Fig. 2. Band shift assay of the complex formation between R42 and 
the labelled 57-bp HIV enhancer DNA on a 12% polyacrylamide gel. 
Lane 1, HIV enhancer DNA alone; lane 2, DNA-binding domain of 
434 repressor (Fig. lb, 35 pmol); lanes 36, R42 (Fig. Id, 10, 15, 20, 
and 35 pmol, respectively). 
polyacrylamide gels. Electrophoresis was run at 200 V for 4.5 h in 22.5 
mM Tris-borate. Gels were analyzed by autoradiography. 
2.3. DNase I footprmt analysis [13] of the R42-HIV enhancer DNA 
interaction (Fig. 3) 
Peptides were incubated with labelled 57-bp enhancer DNA (500 
fmol each) in 100,~l buffer (10 mM Tris-HCI, pH 7.5, 100 mM NaCl, 
50 mM KCl, 5 mM MgCI,, 1 mM CaCl,, 0.25 mM EDTA) for 15 min 
at 37°C. Each mixture was treated with DNase I (1 pg in 5 ~1 buffer) 
for 2 min at 22°C. The digests were precipitated and redissolved as 
described [12], heated to 90°C for 2 mitt, chilled, and applied to a 
denaturing 10% polyacrylamide gel (5 ,~l or -12,000 cpm per lane). 
Electrophoresis was in 10 mM Tris-HCl. pH 7.5, 1 mM EDTA at 
2,000 v. 
2.4. In vitro transcription of recombinant plasmi& in the presence of 
R42 
Plasmid pCDl2 [14.15] was isolated from pCDl2-transformed 
E. coli AGl using Qiagen anion-exchange columns. Cleavage by NcoI 
and isolation of the linearized plasmid followed standard procedures 
[12]. HeLa whole-cell extract was prepared by the method of Manley 
et al. [16]. The protein concentration of the dialyzed extract was 11 
mg/ml. Standard in vitro transcription mixtures (50 ~1) [14] contained 
HeLa cell extract and NcoI-cleaved pCDl2 (1.2 pg each) preincubated 
for 15 min at 37°C with R42 or the DNA-binding domain of 434 
repressor (Fig. lb). Incubations were terminated after 2.5 h at 30°C 
by adding Promega stop solution and the transcripts isolated [12] and 
then separated on denaturing 6% polyacrylamide gels in 10 mM Tris- 
HCl, pH 7.5, 1 mM EDTA, 1% SDS at 200 V. Control plasmid 
OVEC-1 [17] was isolated from OVEC-transformed E. coliHBlO1 and 
linearized by EcoRI cleavage. In vitro transcription and isolation and 
separation of the transcripts were as described for pCDl2. 
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Fig. 3. DNase I footprint analysis of the interaction of R42 and two 
R42 analogues with the labelled 57-bp HIV enhancer DNA. Lane 1, 
DNase I digestion in the absence of protein; lanes 2 and 3, digestion 
in the presence of the DNA-binding domain of 434 repressor (Fig. lb, 
100 and 250 pmol resp.); lanes 46, digestion in the presence of R42 
Arg’2, R42, and R42 Arg 32 Glu” (100 pmol each resp.). Lanes G, , 
A+G, T+C, and C show the sequence analysis of the 5’-labelled 57-bp 
HIV enhancer DNA. R42 Arg” and its DNA-binding properties will 
be described elsewhere. 
3. RESULTS AND DISCUSSION 
3.1. DNA binding speciJicity of R42 
The operator-binding domain of 434 repressor (Fig. 
lb) did not interact with a 57-bp HIV enhancer DNA 
(Fig. le) whereas the 434 repressor-derived construct 
(R42, Fig. Id) bound strongly. Gel electrophoresis 
showed that low and high molecular mass complexes 
were formed (Fig. 2) depending on the peptide concen- 
tration of the incubation mixture [l 11. CD titration of 
enhancer DNA with R42 up to a fivefold molar excess 
of peptide indicated that the mode of binding was 
unique (manuscript in preparation). 
In order to study how the sequence specificity of the 
recognition helix was affected by the positive charges at 
the N- and C-terminus of R42, the band shift assays 
were repeated in the presence of sonicated calf thymus 
DNA and HIV enhancer DNA, lacking the potential 
target sequences ACAAG and AC’ITT (Fig. If), as 
competitors. It was found that a loo-fold excess of the 
competitor DNAs displaced 43% and 50%, respectively, 
of bound labelled HIV enhancer DNA (Fig. le) indicat- 
ing that despite the many positive charges R42 had 
retained binding specificity. This was confirmed by 
DNA melting studies. In the presence of an equimolar 
amount of R42 (2 x 10m8 M) the melting temperature of 
the HIV enhancer DNA rose from 73.2 to 75.2”C 
whereas that of the enhancer DNA lacking ACAAG 
and ACTTT increased only from 74.4 to 74.6”C. 
DNase footprinting [13] in connection with sequence 
analysis [18] of the synthetic HIV enhancer DNA re- 
vealed that the region that was protected from DNase 
I digestion by R42 (Fig. 3, lane 5, and sequence marked 
by heavy bar in Fig. le) extended several base pairs 
beyond the ACAAG and ACTlT segments. The opera- 
tor-binding domain of 434 repressor (Fig. lb) could not 
protect HIV enhancer DNA (Fig. 3, lanes 2 and 3). 
3.2. Inhibition of HIV LTR-controlled in vitro transcrip- 
tion by R42 
Okamoto and Wong-Staal[14] had shown that addi- 
tion of NcoI-cleaved recombinant plasmid pCD12 
[14,15] (Fig. 4a), containing the LTR region of HIV-l, 
to HeLa whole-cell extract [ 161 resulted in RNA polym- 
erase II-catalyzed synthesis of a 633-nucleotide tran- 
script (Fig. 4b, lane 2). In the presence of R42 the for- 
mation of this transcript was inhibited (Fig. 4b, lane 5). 
Complete suppression of transcription of 1.2 ,ug NcoI- 
cleaved pCD12 required 0.25 pg of R42 which probably 
interfered with the HIV enhancer binding of HeLa cell 
proteins such as EBP-1 [19] and NF-FOB [6,20] and thus 
acted as artificial repressor. It did not block the tran- 
scription of the 18s rRNA gene [14] (Fig. 4b, lane 5). 
Suppression of the cell-free in vitro transcription of the 
recombinant control plasmid OVEC-1 [17] which has 
six upstream ACAA segments but no HIV enhancers 
required -10 times the amount of R42 that inhibited 
the transcription of pCD12 (Fig. 4~). 
3.3. Characterization of the Arti’, G1d3-analogue of 
R42 
Gln33 of 434 repressor contributes to the specific rec- 
ognition of $1 and $g of the 434 operators through 
hydrogen bonds of its amide side-chain with C?=O of 
T and (?-NH, of A or C4-NH2 of C [3]. In order to shift 
the binding specificity to F* of the ACTTT sequences of 
the HIV enhancers (Fig. la), Gln33 was replaced by 
glutamic acid because the side-chain of the latter would 
be a better acceptor of the two hydrogen bonds with the 
C6-NH2 groups of the adjacent adenines. To avoid clus- 
tering of negative charges in the recognition helix 
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Fig. 4. (a) control region and single NcoI site of recombinant pCD12. (b) gel electrophoretic analysis of the effect of R42 on in vitro transcription 
of NcoI-cleaved pCD12 in HeLa whole-cell extract (141. Lane 1, transcription in the absence of plasmid; lane 2, transcription in the presence of 
plasmid; lane 3, plasmid and DNA-binding domain of 434 repressor (500 pmol); lane 4, plasmid and R42 (25 pmol); lane 5, plasmid and R42 (50 
pmol); lane 6, plasmid and a-amanitin (0.5 &ml) which inhibits RNA polymerase II-catalyzed transcription. Upper arrow, position of 18s rRNA 
[14]; lower arrow, position of run-off transcript of NcoI-cleaved pCD12. (c) effect of R42 on in vitro transcription of EcoRI-cleaved OVEC-1 [I 71 
in HeLa cell extract. Lane 1, transcription in the presence of plasmid and R42 (250 pmol); lane 2, plasmid and R42 (100 pmol); lane 3, plasmid 
without peptide; lane 4, transcription in the absence of plasmid. The arrow marks the position of the 989-nucleotide run-off transcript of 
EcoRI-cleaved OVEC-I. In b and c, the isolated transcripts were dissolved in 40 ~1 formamide buffer each and 5 ~1 applied per lane. 
1 2 3 4 5 
Fig. 5. Band shift assay of the complex formation of R42, R42 
Arg3ZGlu33, and R42 Arg” (10 pmol each) with labelled HIV enhancer 
DNAs on an 8% polyacrylamide gel. Lane 1, HIV enhancer DNA 
lacking ACAAG; lane 2, HIV enhancer DNA lacking ACAAG + R42; 
lane 3, HIV enhancer DNA lacking ACITT + R42 Arg3ZGlu33; lane 
4, HIV enhancer DNA lacking ACAAG + R42 Arg32Glu33; lane 5, 
HIV enhancer DNA lacking ACAAG + R42 Arg3’. 
(G1u32~33~35), Gl u32 was changed to arginine yielding the 
Arg32,Glu33-analogue. 
Fig. 5 shows that the binding specificity of R42 
Arg32,Glu33 was indeed shifted toward ACTTT (lanes 3 
and 4) and that the R42 analogue bound twice as much 
of an enhancer DNA lacking ACAAG than R42 (lanes 
2 and 4). These results confirm the importance of Gln33 
of 434 repressor for the specific recognition of the target 
DNA and represent a first step toward improving the 
binding specificity of our R42 construct. 
4. OUTLOOK 
Elucidation of the structure in solution and in the 
crystal of the complex of R42 with HIV enhancer DNA 
is a realistic goal and may give us useful hints for the 
design of R42 analogues with improved HIV enhancer 
binding specificity. The genes of these analogues could 
be expressed in HIV-infected cells using a recombinant 
virus [21] and the gene products might suppress the 
transcription of HIV-l and thus provide intracellular 
immunity 1221. The major problem would be that we do 
not know if the expression of cellular genes would also 
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be affected. In this respect, it might be of advantage that 
R42 has intermediate affinity for its target sequence(s). 
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